The shadow of generic competition has consistently loomed above copyright’s famous drug, Sildenafil, raising questions about the prospects of connected medicinal holdings. While first times saw substantial gains, the exclusivity expiration has opened the door for cheaper alternatives, likely reducing earnings and creating a genuine hazard for sha